F2RL1 and neoplasm: Despite increasing evidence of trypsin induced activation of PAR-2 in cancer progression in other neoplasms, including digestive tract tumors such as gastric and colonic cancers, the functional consequences of trypsin evoked PAR-2 activation in esophageal cancer has not yet been reported.